We are excited to announce that Cureline Baltic, a company specializing in oncology, autoimmune and microbiota research, has officially joined the #PharmaxiPartnershipNetwork! With its innovative double cellular barcoding technology - MetTrackerTM - Cureline Baltic is revolutionizing preclinical research, reducing study timelines, and optimizing animal models. As a trusted provider of cutting-edge scientific services, the Company offers: ✔️Preclinical Animal Research ✔️In Vitro Preclinical Research ✔️Biospecimen Procurement & Analysis ✔️R&D Consulting This partnership represents an important step in expanding our Network and enhancing collaboration across the preclinical and clinical sectors. By working together, we aim to deliver exceptional services tailored to the diverse needs of our clients, driving innovation and excellence in healthcare research. We look forward to driving progress together! #biotech #drugdiscovery #preclinicalresearch #partnership #innovation
Pharmaxi LLC’s Post
More Relevant Posts
-
Don't FRET if you missed Day 1 because of prior commitments it will go On-Demand! It had some incredible talks covering the latest in Multi-omics and Microbiome research and approaches. Hats off to all the researchers and scientists that are working diligently to drive biology understanding! Day two is here and check out our lineup below! #multiomics #microbiome #freeevent #scienceandtechnology #researchanddevelopment #precisionmedicine #knowledge
Multi-Omics & Microbiome Virtual Conference Day 2 - Wednesday, June 12th Speaker Lineup: 1) Christopher B Ford from Seres Therapeutics 2) Shameer Khader, Ph.D, MPH from Sanofi 3) Sergio Barberan-Soler from RealSeq Biosciences 4) Tao Pan from University of Chicago 5) Stephanie Servetas from National Institute of Standards and Technology (NIST) 6) Niokhor Dione from AnimalBiome 7) Kristen Muñoz, Ph.D. Morrison Foerster 8) Nita Madhav from Ginkgo Bioworks, Inc. 9) Trent Munro from Microba Life Sciences Click below to register for free and check out talk titles and abstracts. #multiomics #microbiome #freeevent #virtualconference https://lnkd.in/eGtYqmuE
-
Raphaël G. Ognar, MSc MBA, distinguished as the visionary CEO and Founder of NKILT Therapeutics, Inc., graced the esteemed stage as the harbinger of innovation during the inaugural presentation of our illustrious Alcor Drug Discovery Platform (ADDP) Day at the opulent New Jersey Crown Plaza. With profound expertise and captivating charisma, he assumed the pivotal role of Chairperson for the enlightening second day of our distinguished event. #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug
-
-
While it’s great to celebrate successes, I believe there’s also value in sharing the setbacks. Our Eurostars project at Netabolics was recently rejected. This isn’t the first time, and it definitely won’t be the last, but it gives me a chance to share a couple of important thoughts. First, I’m still fully committed to our mission of transforming drug discovery and repurposing using genome-scale biosimulation. Second, I’m actively looking for mission-aligned partners to help move this technology forward. If you’re curious, take a moment to check out the video below. It’s a quick look at what we’re working on, including an example we recently presented at the #RExPO24 conference. It’s a bit technical, but intentionally so. While publication isn't our top priority right now, we also expect to have a full paper ready by mid-late next year. If you’re part of an academic lab or a biotech company and want to collaborate, let’s talk. Together, we can push innovation forward for the benefit of patients. https://lnkd.in/dskcf5AY #PrecisionOncology #Partnerships
Reimagine precision oncology with genome-scale biosimulation
https://www.youtube.com/
-
| Building a Global Talent Solutions Revolution | Executive Pharmaceutical Headhunter | Vector |
✨ ✨ ✨ I'd like to kick off a new series highlighting some of the best and brightest across the Life Science space ✨ ✨ ✨ My first instalment of this kicks off with a company doing incredible work in the Drug Design space... 🥁 🥁 Exscientia 🔎 They utilise precision information derived from patient tissues alongside sophisticated AI technology to source optimised drug profiles for research. This integrated system has been the first to demonstrate improved clinical outcomes in oncology, and I believe that is just the beginning in their revolution. 📈 They currently have four targets at pre clinical, and phase 1-2, across Haematology, Oncology, and Inflammatory Diseases. With 40% of total clinical growth within Biotech/ Pharmaceuticals sitting within Oncology in 2023, Exscientia should be on your radar! 🗞 With the recent appointment of Marie-Louise Fjaellskog, and promotion of John Overington, I can't wait to see the continued success of this truly pioneer company. #Biotech #innovation #AI #DrugDesign
-
-
There are so many rodent models available for preclinical target and drug discovery for #MASH. But which model offers the highest resemblance of the human disease? The answer is simple. In the recent issue of Nature Metabolism, the renowned #LITMUS consortium concludes that Gubra’s GAN DIO-MASH mouse model ranks #1 for human proximity, a key indicator of clinical translatability, in terms of both metabolic relevance and ability to induce MASH-fibrosis. LITMUS compared a wide range of the most commonly used preclinical MASH models, evaluating their metabolic phenotype, liver histopathology and transcriptomics against corresponding MASH patient data. We are very proud and grateful to be recognized by LITMUS as the provider of the most translational preclinical model. Check out the paper and explore the objective ranking of preclinical models of MASH in the industry. #PreclinicalModel #PreclincalResearch #ClinicalTranslatability #MASLD #Publication #PreclinicalCRO #ResearchModels
-
The development and optimization of novel radioligands for drug development applications is critical to move new compounds from bench to bedside. Join Dr. Lisa Wells, Head of Discovery CNS Application, as she provides an overview of a typical study design for the development of a suitable PET radioligand for a novel target in CNS disease models; explains the importance of determining target expression in the tissue(s) of interest and candidate ligand characteristics prior to in vivo imaging; and explores how data is analyzed in preclinical animal models, non-human primates and human subjects. #PET #SPECT #CNS #radioligand https://hubs.ly/Q02qgjhS0
-
-
Thank you Elizabeth Eaton for this wonderful article covering Rubedo Series A!
Rubedo Life Sciences has spent the last six years meticulously laying the groundwork for its pipeline of senescent cell-targeting treatments -- a field that grabbed headlines in the late 2010s for its anti-aging potential. "We didn't want to rush, we wanted to make sure that we were solid before embarking into clinical development. And now we are ready," CEO Marco Quarta told me. Now, flush with a $40-million series A, the biotech plans to enter the clinic this year with its lead senolytic to treat atopic dermatitis and psoriasis: diseases with unmet patient need, carefully selected as the best to demonstrate clinical proof-of-concept. For more on how Rubedo has navigated the senescent cell space, read here: https://lnkd.in/g23Ens2h
With fresh $40M, Rubedo outlines senescent roadmap
ml.firstwordpharma.com
-
🙌 I am thrilled to share that Ochre Bio, one of our innovative portfolio companies, has entered into a groundbreaking, up to $1 billion partnership with Boehringer Ingelheim to advance treatments for metabolic-associated steatohepatitis (MASH), a severe form of liver disease. 🧬 Ochre Bio is at the forefront of chronic liver disease medicine development and RNA biotechnology, developing therapies that harness the liver's regenerative capabilities to combat chronic liver diseases. This collaboration will leverage Ochre Bio's expertise, proprietary discovery platform in liver disease research, genomics, and machine learning to target disease pathways effectively, offering new hope in a challenging therapeutic area. 👏 As an investor, it's incredibly rewarding to support and be part of solutions that promise significant impacts on patient health globally. This partnership not only underscores Ochre Bio's potential but also marks a significant step towards transformative healthcare solutions. 🥂Congratulations to the team at Ochre Bio! I can't wait to see more innovation and see how we can make a meaningful difference in the lives of those affected by chronic liver disease. #Biotech #HealthcareInnovation #Partnership #VentureCapital #Biotechnology #VC #LiverHealth #RNAtherapy #BiotechInvestment #HealthTech #InnovationInHealthcare #ChronicDiseaseManagement #MedicalResearch #BiotechVC #StartupGrowth #CollaborativeInnovation #FutureOfMedicine
🎉 Announcing our new partnership with Boehringer Ingelheim to discover and develop novel regenerative treatments for chronic liver disease! Our multi-year collaboration will focus on using our proprietary discovery platform – which combines advanced genomics, deep phenotyping and machine learning – and human-organ translational models to accelerate the development of novel targets for undertreated liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. The deal brings in up to $35m in upfront and near-term milestone payments, with late preclinical, clinical, regulatory and commercial milestones with the potential to exceed $1B, as well as tiered commercial royalties. Chronic liver disease (CLD) and associated cirrhosis accounts for approximately 1 million deaths per year. Currently there are no approved medicines for cirrhosis resulting from CLD and there is an urgent need for new effective treatment options. The partnership is part of Boehringer Ingelheim’s commitment to improving the lives of people living with liver diseases. Together we will continue to pioneer liver regeneration research, with a shared vision of reversing the progression of diseases that affect millions worldwide. Read our full announcement ➡️ https://lnkd.in/ePFjWumn #TeamOchre #biotech #genomics #LiverDisease
-
Rubedo Life Sciences has spent the last six years meticulously laying the groundwork for its pipeline of senescent cell-targeting treatments -- a field that grabbed headlines in the late 2010s for its anti-aging potential. "We didn't want to rush, we wanted to make sure that we were solid before embarking into clinical development. And now we are ready," CEO Marco Quarta told me. Now, flush with a $40-million series A, the biotech plans to enter the clinic this year with its lead senolytic to treat atopic dermatitis and psoriasis: diseases with unmet patient need, carefully selected as the best to demonstrate clinical proof-of-concept. For more on how Rubedo has navigated the senescent cell space, read here: https://lnkd.in/g23Ens2h
With fresh $40M, Rubedo outlines senescent roadmap
ml.firstwordpharma.com
-
🌟 StarkAge Therapeutics Reaches a New Milestone with the Creation of Its Advisory Boards 🌟 We are proud to announce the establishment of our Advisory Board and Scientific Advisory Board, marking a pivotal step in StarkAge’s journey toward becoming a mature and structured biotech. These boards bring together internationally renowned experts to guide us through the next phases of our growth and innovation. 💡 Boards Designed for Excellence and Long-Term Vision With this new governance structure, StarkAge aligns with the standards of the most advanced biotech companies, solidifying its strategic and scientific foundations. 🧬 A World-Class Scientific Advisory Board Comprising global leaders in oncology and aging biology, including: 🔹 Dr. Éric Angevin (Gustave Roussy) 🔹 Prof. Cléo Bishop (Queen Mary University of London) 🔹 Dr. David Bernard (CNRS, CRCL) 🔹 Dr. Fabrizio d’Adda di Fagagna (CNR, Italy) 🔹 Prof. Michail Ignatiadis (Jules Bordet Institute) 💼 A Strategic Advisory Board to Support Our Growth Featuring experts in biotech financing, international expansion, and strategic management: 🔹 François Descamps 🔹 Georges Lotigier 🔹 Dr. Laurent Jacqueroud PhD 🔹 Dr. Florence Lhospice PhD 🔹 Dr. Laurent Metz MD, PhD, MBA (Harvard) 🔹 Cédric Mathieu HEC (Graduate) With this strengthened governance, StarkAge Therapeutics is solidifying its position as a mature and visionary biotech, ready to accelerate the development of innovative therapies targeting cancer and cellular senescence. 🚀 📩 For more information: Contact us at thierry.mathieu@starkage.com #Biotech #Innovation #Health #Governance #StarkAgeTherapeutics #oncology #senescence
Well done Yurii Lebіd !!